玻璃体腔注射雷珠单抗治疗老年性黄斑变性的疗效分析  

Clinical Analysis of Intravitreal Injection of Ranibizumab in Treatment of Age-related Macular Degeneration

作　　者：吕达[1] 

机构地区：[1]益阳爱尔眼科医院眼科,湖南益阳413000

出　　处：《中国卫生标准管理》2017年第13期95-97,共3页China Health Standard Management

摘　　要：目的探讨玻璃体腔注射雷珠单抗治疗老年性黄斑变性的临床疗效。方法回顾性分析2016年3月—2017年1月我院54例老年性黄斑变性患者的临床资料,将入选的患者随机平均分为对照组和研究组,对照组27例患者给予视网膜光凝治疗,研究组27例患者给予玻璃体腔注射雷珠单抗治疗,比较两组患者的治疗效果。结果治疗后两组患者最佳矫正视力及CMT均显著改善,且研究组患者改善程度优于对照组,两组比较差异有统计学意义(P<0.05),研究组无明显渗漏患者占比高于对照组,两组比较差异有统计学意义(P<0.05)。结论玻璃体腔注射雷珠单抗能有效改善老年性黄斑变性患者病情,提高视力水平,疗效安全可靠,具有重要的临床应用价值。Objective To explore the effects of intravitreal injection of ranibizumab in treatment of age-related macular degeneration. Methods 54 age-related macular degeneration patients from March 2016 to January 2017 were selected and divided into control group（n=27） and research group（n=27） randomly. The control group was treated with retinal photocoagulation and the research group was taken intravitreal injection of ranibizumab. The clinical effects between the two groups were compared. Results After treatment, best corrected visual acuity and CMT were improved in the two groups and the improvement was more significant in research group（P〈0.05）. The non-seepage rate in research group was lower than that of control group（P〈0.05）. Conclusion Intravitreal injection of ranibizumab in treatment of age-related macular degeneration can improve condition with safety and curative effect.

关 键 词：玻璃体腔 雷珠单抗 老年性黄斑变性 视力 临床疗效 

分 类 号：R774.5[医药卫生—眼科]